BioXcel Therapeutics Rings Nasdaq Opening Bell

April 20, 2018

1Clinical Pipeline

2Emerging pipeline

Transforming Drug Discovery for the Next Wave of Medicines

BXCL501 Treating the Symptoms of Neuropsychiatric and Neurodegenerative Diseases

BXCL701 Revolutionizing drug development and translation research in Immuno-Oncology (IO)

BXCL702 Developing the drug as mono-therapy and in combination with immune-checkpoint inhibitors

Learn more

The Healing Power of Science

Medicines that change lives



Targeting immuno-oncology and neuroscience disorders with significant unmet medical need



Proprietary drug re-innovation approach to other underserved areas in oncology and neuroscience


Higher Probability

Generating first in class drug candidates with a higher probability of clinical and regulatory success


Therapeutic Benefit

Potential to provide significant therapeutic benefit to the patients who need close medical attention

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company that utilizes novel artificial intelligence, or AI, to identify the next wave of medicines across neuroscience and immuno-oncology.
Our drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. We believe that this differentiated approach has the potential to reduce the cost and time of drug development in diseases with substantial unmet medical need.


Press Coverage

January 9, 2019

BioXcel Therapeutics Included in list of “The Most Innovative Healthcare AI Developments of 2019”

View all Press Coverages

News Releases

July 1, 2019

BioXcel Therapeutics Added to Russell 3000® Index

View all News Releases